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Abstract
Objective—To examine ADHD symptom persistence and subtype stability among substance use 
disorder (SUD) treatment seekers.
Method—In all, 1,276 adult SUD treatment seekers were assessed for childhood and adult 
ADHD using Conners’ Adult ADHD Diagnostic Interview for Diagnostic and Statistical Manual 
of Mental Disorders (4th ed.; DSM-IV; CAADID). A total of 290 (22.7%) participants met 
CAADID criteria for childhood ADHD and comprise the current study sample.
Results—Childhood ADHD persisted into adulthood in 72.8% (n = 211) of cases. ADHD 
persistence was significantly associated with a family history of ADHD, and the presence of 
conduct disorder and antisocial personality disorder. The combined subtype was the most stable 
into adulthood (78.6%) and this stability was significantly associated with conduct disorder and 
past treatment of ADHD.
Conclusion—ADHD is highly prevalent and persistent among SUD treatment seekers and is 
associated with the more severe phenotype that is also less likely to remit. Routine screening and 
follow-up assessment for ADHD is indicated to enhance treatment management and outcomes.
Keywords
ADHD; subtypes; persistence; substance related disorders
Introduction
ADHD is characterized by inattention, hyperactivity, and/or impulsivity. Symptoms have 
historically been labeled as predominantly inattentive, predominantly hyperactive-impulsive, 
or combined “subtypes” of ADHD, although the Diagnostic and Statistical Manual of 
Mental Disorders (5th ed.; DSM-5; American Psychiatric Association [APA], 2013) 
replaced the term “subtypes” with “presentations” to reflect the observation that symptoms 
can manifest differently over time. As individuals with ADHD become older, symptoms can 
decrease in severity, with inattentive symptoms generally being more persistent than 
hyperactive-impulsive symptoms (Turgay et al., 2012; Wilens et al., 2009).
Although ADHD is often described as a childhood disorder, and can remit over time, ADHD 
symptoms persist into adulthood in about two thirds of cases, with associated impairment 
across multiple domains (Biederman, Petty, Evans, Small, & Faraone, 2010; Faraone, 
Biederman, & Mick, 2006; Turgay et al., 2012). Previous research has identified several risk 
factors for the persistence of childhood ADHD into adulthood: a family history of ADHD 
(Biederman et al., 1996; Biederman et al., 2010; Biederman, Petty, O’Connor, Hyder, & 
Faraone, 2012), ADHD symptom severity and associated impairment (Biederman, Petty, 
Clarke, Lomedico, & Faraone, 2011; Kessler et al., 2005; Lara et al., 2009), and comorbidity 
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with conduct, oppositional defiant, mood, and anxiety disorders (Biederman et al., 1996; 
Biederman et al., 2011; Biederman et al., 2010; Biederman et al., 2012; Lara et al., 2009). 
Early psychosocial adversity, exposure to family conflict and parental psychopathology in 
particular, has also been shown to predict ADHD persistence (Biederman et al., 1996; 
Biederman et al., 2011; Biederman et al., 2012; Lara et al., 2009). Although the diagnosis of 
adult ADHD is based on clinical presentation and history, there is evidence to suggest that 
persistent ADHD can also be differentiated from remitted ADHD at the neurobiological 
level, including the presence of structural and functional brain differences between those 
with persistent and remitted ADHD (Mattfeld et al., 2014; Shaw et al., 2015).
Childhood ADHD is a well-documented, independent risk factor for the development of 
substance use disorders (SUDs) in adolescence and adulthood (Charach, Yeung, Climans, & 
Lillie, 2011; Lee, Humphreys, Flory, Liu, & Glass, 2011; Wilens et al., 2011) and is 
consistently overrepresented among SUD populations (van Emmerik-van Oortmerssen et al., 
2012). Moreover, ADHD is associated with an earlier onset, greater severity, and increased 
chronicity of problematic substance use (Arias et al., 2008; Sullivan & Rudnik-Levin, 2001; 
Wilens et al., 2011).
The persistence of ADHD symptoms beyond childhood further increases the likelihood of 
comorbid SUDs, with SUDs far more common among people with adult ADHD than among 
those with remitted childhood ADHD (Biederman et al., 2010; Molina & Pelham, 2003; 
Sullivan & Rudnik-Levin, 2001; Wilens et al., 2011). Increased risk of SUDs has also been 
reported in adults with subthreshold symptoms of ADHD (Faraone et al., 2007).
The risk of those with ADHD developing subsequent SUDs is not only increased among 
those with persistent ADHD symptoms, but also among those with particular symptom 
types, that is, with the hyperactive-impulsive (Chang, Lichtenstein, & Larsson, 2012; Elkins, 
McGue, & Iacono, 2007) or combined (Nogueira et al., 2014; Obermeit et al., 2013; 
Sprafkin, Gadow, Weiss, Schneider, & Nolan, 2007; Tamm, Adinoff, Nakonezny, Winhusen, 
& Riggs, 2012; Wilens et al., 2009) subtypes of ADHD. To date, however, factors associated 
with the persistence and presentation of ADHD symptoms among people with SUDs have 
received scant attention. Moreover, whether SUD trajectories differ between those whose 
ADHD symptoms remit versus persist, and between those with different ADHD subtypes, 
remains unclear. The current study examines (a) the persistence of ADHD symptoms into 
adulthood among people seeking treatment for SUDs, (b) correlates and childhood 
predictors of persistent ADHD, and (c) the stability of ADHD subtypes between childhood 
and adulthood.
Method
Data for this study were collected as part of the International ADHD in Substance Use 
Disorders Prevalence (IASP) study (van de Glind et al., 2013), a multi-site, cross-sectional 
study of ADHD among SUD treatment seekers conducted by the International Collaboration 
on ADHD and Substance Abuse (ICASA). The IASP study had approval from relevant 
ethics committees in each site and comprised two phases—a screening phase and a full 
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assessment phase. For further details of the methodology of the IASP study, see van de 
Glind et al. (2013).
Participants
All individuals referred to recruiting drug and alcohol treatment centers during the study 
period (July 2008–November 2011) were invited to participate. Exclusion criteria were the 
inability to complete the screening questionnaire (e.g., due to limited literacy and/or 
cognitive impairment), severe physical or psychiatric problems, the inability to participate 
due to substance intoxication, and unwillingness to sign informed consent.
A total of 3,558 adults (aged 18–65 years) attending 47 drug and alcohol treatment centers 
in 10 countries (Australia, Belgium, France, Hungary, Norway, Spain, Sweden, Switzerland, 
Netherlands, and the United States) were screened for the presence of ADHD (screening 
phase). Screening interviews were conducted upon treatment intake. With the exception of 
those screened in Australia, Belgium, and the United States (n = 963), all screened 
participants were invited to participate in a further comprehensive psychiatric interview that 
took place 1 to 2 weeks after screening (full assessment phase), allowing for a period of 
patient stabilization in treatment.
Of the 3,558 participants screened, 1,276 completed the full assessment, during which they 
were evaluated for the presence of SUDs, childhood and current (adult) ADHD, and other 
comorbid psychiatric disorders. Detailed information on sample characteristics and ADHD 
prevalence can be found in van de Glind et al. (2014; van de Glind et al., 2013). A previous 
investigation indicated that there were no significant differences in terms of 
sociodemographic and clinical characteristics between the 1,276 participants completing the 
full assessment and the 1,319 participants who dropped out of the study after the screening 
phase (van de Glind et al., 2013).
Of those participants completing the full assessment, 290 (22.7%) met criteria for a DSM-5 
diagnosis of childhood ADHD and thus comprise the current study sample.
Measures
During the screening phase, a brief structured interview assessing demographics, past and 
current drug use, and details of current treatment episode was administered. Drug use history 
was ascertained by asking about the age of first use, years of regular use, and recent (30 days 
preceding treatment entry) use of alcohol, tobacco, heroin, methadone, opioids other than 
heroin or methadone, amphetamines, cocaine, ecstasy, benzodiazepines, and cannabis. 
Participants were also asked to specify their primary drug of current concern.
Diagnoses of ADHD were ascertained using Conners’ Adult ADHD Diagnostic Interview 
for Diagnostic and Statistical Manual of Mental Disorders (4th ed.; DSM-IV; APA, 1994; 
CAADID; Epstein, Johnson, & Conners, 2001). Part I of the CAADID was self-
administered and obtains information on obstetric complications (e.g., maternal substance 
use during pregnancy, premature birth, low birth weight), temperamental characteristics 
(e.g., impulsivity, hyperactivity), developmental milestones, environmental circumstances 
(e.g., trauma, neglect, family violence), medical history, and familial psychiatric problems to 
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assess early risk factors for ADHD. Past and current social, academic, and occupational 
functioning is also assessed.
Given the high rates of childhood trauma among SUD populations (Conroy, Degenhardt, 
Mattick, & Nelson, 2009; Farrugia et al., 2011), the current study employed the CAADID to 
examine childhood adversity (i.e., physical, emotional, and sexual abuse; parental neglect; 
family violence; and other childhood trauma) as a potential risk factor for the persistence of 
ADHD. Self-reported familial risk factors (i.e., family history of diagnosed ADHD) and in 
utero substance (i.e., nicotine, alcohol, illicit drug) exposure, as measured by the CAADID, 
were also investigated as predictors of ADHD persistence.
Part II of the CAADID, administered by trained health professionals, is a semi-structured 
interview, assessing the five Diagnostic and Statistical Manual of Mental Disorders (4th ed., 
text rev.; DSM-IV-TR; APA, 2000) criteria for childhood and adult ADHD: (a) number of 
symptoms, (b) age of onset, (c) symptom pervasiveness, (d) level of impairment, and (e) 
whether or not the symptoms can be better explained by another psychiatric disorder. To 
obtain DSM-5 diagnoses of ADHD, the age of onset threshold was increased from <7 years 
to <12 years and the number of symptoms required for an adult diagnosis reduced from six 
out of nine symptoms of inattention and/or hyperactivity-impulsivity to five out of nine 
symptoms (APA, 2013). A diagnosis of adult ADHD was contingent on a retrospectively 
obtained diagnosis of childhood ADHD meeting all five criteria, including the presence of 
six or more symptoms in childhood. This procedure results in conservative estimates of adult 
ADHD prevalence, as it is stricter than the DSM criteria for adult ADHD, which only 
require that “several” symptoms must be present before the age of 12.
An additional measure of adult ADHD was provided by the ADHD module of the Mini 
International Neuropsychiatric Interview (MINI-Plus; Sheehan et al., 1998). The MINI-Plus 
was also used to assess prior and current episodes of mood disorders (i.e., major depression, 
bipolar disorder) and antisocial personality disorder (ASPD). Conduct disorder (CD) was 
retrospectively assessed using the ASPD module of the MINI-Plus, which establishes 
evidence of CD symptoms with an onset before the age of 15. The borderline personality 
disorder module of the Structured Clinical Interview for DSM-IV Axis II Personality 
Disorders (SCID II; Williams et al., 1992) was also used. For details of the nature and level 
of comorbidity in this sample, see van Emmerik-van Oortmerssen et al. (2014).
Data Analysis
Initially, univariable analyses were conducted to identify statistically significant associations 
between demographic, drug use, and clinical variables and ADHD persistence. For 
continuous variables, t tests were employed. For dichotomous categorical variables, 
unadjusted odds ratios (OR) and 95% confidence intervals (CI) were reported. All primary 
statistical tests were determined significant at an alpha level of p < .05. Where multiple 
comparisons were conducted, Holm–Bonferroni corrections were performed to control the 
familywise error rate at p < .05.
To identify factors independently associated with persistence of ADHD symptoms and 
stability of ADHD subtypes, multivariable logistic regression analyses were conducted. Due 
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to the hierarchical structure of the data, where participants were nested within sites (i.e., 
treatment centers), potential clustering by site was taken into account. Intracluster (or 
intraclass) correlation coefficients (ICCs), which provide a measure of the proportion of 
outcome variance attributable to between-cluster variance, with values close to 0 indicating 
negligible within-site clustering, were calculated for outcome variables of interest. Although 
the ICCs for the primary outcomes of ADHD persistence and subtype stability were less 
than .1 (ρ = .05 and ρ = .06, respectively), we took a conservative approach and used the 
SPSS Complex Samples module, which adjusts for clustering. All regression models were 
adjusted at the participant level for age, gender, ethnicity (Caucasian = yes/no), level of 
education (graduated high school = yes/no), CD symptoms (yes/no), and past treatment of 
ADHD with stimulant medication (yes/no). All analyses were conducted using IBM SPSS 
Statistics 22 (IBM Corp, 2013).
Results
Persistence of ADHD
Of the 290 participants meeting childhood criteria for ADHD, 211 also met criteria for adult 
ADHD, representing a persistence rate of 72.8%, and thus comprised the “persistent 
ADHD” group. The remaining 79 who did not meet criteria for adult ADHD comprised the 
“remitted ADHD” group.
There was no significant association between the age of the participant and the likelihood of 
full syndrome ADHD persistence (OR = 0.99, 95% CI = [0.97, 1.02], p = .703). Likewise, 
age was not associated with the persistence of ≥5 symptoms from either the inattentive (OR 
= 0.99, 95% CI [0.97, 1.01], p = .374) or hyperactive-impulsive (OR = 0.98, 95% CI = [0.96, 
1.01], p = .152) domains.
Correlates of ADHD Persistence
Sociodemographic and treatment characteristics—As shown in Table 1, there were 
no significant sociodemographic differences or differences in the type of treatment setting 
(i.e., inpatient vs. outpatient) between the persistent ADHD and remitted ADHD groups.
Substance use history—In 60% of cases, illicit drugs, most commonly cannabis (17%), 
amphetamines (15%), and heroin (11%), were nominated as the primary drug of concern 
upon entry to treatment. Of the 40% who nominated alcohol as their primary drug of 
concern, however, one third (33.6%) had also used illicit drugs in the month preceding 
treatment.
Both the persistent and remitted ADHD groups reported initiating nicotine, alcohol, and 
illicit drug use from an average age of 14 onwards (Table 2), at least 2 years after the onset 
of ADHD symptoms in childhood. Those with persistent ADHD reported an earlier 
initiation of amphetamine use, a longer duration of regular cocaine use, and more days of 
cocaine use in the month prior to treatment entry than the remitted ADHD group. The 
persistent ADHD group were more likely to report illicit drugs (vs. alcohol) -amphetamine 
and cocaine in particular - as their primary substance of concern; however, these differences, 
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together with those in substance use initiation, duration, and frequency, did not remain 
significant after Holm–Bonferroni correction (Table 2).
The majority of participants (83.1%) were lifetime polydrug users, with almost half (48.3%) 
engaging in polydrug use in the month prior to treatment. Following correction for multiple 
comparisons, there were no significant between group differences in the extent of either 
lifetime or recent (i.e., month preceding treatment entry) polydrug use (Table 2).
Past ADHD diagnosis and treatment—Less than a quarter (21.9%) of those meeting 
criteria for childhood ADHD had received a diagnosis of ADHD before study entry and an 
even smaller proportion had been treated with stimulant medication (14.5%). There were no 
significant differences between the persistent and remitted ADHD groups with respect to the 
prevalence of past diagnosis and treatment of ADHD (Table 1).
Psychiatric comorbidity—Those with persistent ADHD were significantly more likely 
to meet criteria for ASPD (56.7% vs. 34.7%, OR = 2.46, 95% CI = [1.40, 4.33], p = .002) 
and this association remained significant after Holm–Bonferroni correction (corrected p < .
008) and after adjusting for potential sociodemographic confounders (i.e., age, gender, 
ethnicity, level of education) and past stimulant medication treatment (ORadj = 2.31, 95% CI 
= [1.48, 3.59], p = .001). As ASPD is difficult to disentangle from the behaviors inherent to 
an illicit drug-using lifestyle (e.g., lying, stealing, financial irresponsibility; Darke, Kaye, & 
Finlay-Jones, 1998; Kaye, Darke, & Finlay-Jones, 1998), further regression analysis 
controlling for an illicit SUD was conducted, following which ASPD remained 
independently associated with ADHD persistence (ORadj = 1.84, 95% CI = [1.09, 3.10], p 
= .026).
Although ASPD was associated with the overall persistence of ADHD, this relationship was 
different for adult ADHD subtypes. After adjusting for the aforementioned confounders, 
comorbid ASPD was more likely among those with the combined subtype (ORadj = 2.37, 
95% CI = [1.54, 3.63], p = .001) and less likely among those with the inattentive subtype 
(ORadj = 0.33, 95% CI = [0.12, 0.90], p = .033). There was no significant association 
between ASPD and the hyperactive-impulsive subtype (ORadj = 1.36, 95% CI = [0.36, 5.15], 
p = .633).
Predictors of ADHD Symptom Persistence
Childhood ADHD subtype—Although there were no significant differences in 
proportions with the inattentive subtype in childhood, the persistent ADHD group was more 
likely to meet criteria for the combined subtype and less likely to meet criteria for the 
hyperactive-impulsive subtype than the remitted ADHD group (Table 3). After Holm–
Bonferroni correction, however, these differences were no longer significant.
Familial, environmental, and psychopathological risk factors—Approximately 
one third (30.8%) of the sample had a relative who had been diagnosed with ADHD. A 
family history of ADHD more than doubled the odds of persistent ADHD (Table 3).
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Childhood adversity was highly prevalent among participants meeting criteria for childhood 
ADHD. Of those who completed the section on childhood risk factors for ADHD in Part I of 
the CAADID (n = 246), 83.3% reported having experienced some form of childhood trauma. 
Almost two thirds (65.0%) reported experiencing some type of abuse (i.e., sexual, physical, 
or emotional) in childhood, with emotional abuse the most commonly reported form 
(53.7%). Other types of childhood trauma, including loss of a loved one, physical trauma, 
and witnessing traumatic events, were reported by nearly three quarters of participants 
(71.6%) and over one third had experienced violence within the family (40.7%) and parental 
neglect (36.7%). The persistent ADHD group was more likely to report trauma other than 
abuse, as well as parental neglect, although these differences were no longer statistically 
significant after Holm–Bonferroni correction (Table 3).
Comorbid CD symptoms were prevalent, regardless of ADHD persistence. The odds of CD 
symptoms among the persistent ADHD group, however, were double that among the 
remitted ADHD group (Table 3).
After adjustment for possible confounding, both family history of ADHD (ORadj = 2.28, 
95% CI = [1.12, 4.63], p = .026) and the presence of CD symptoms (ORadj = 2.59, 95% CI = 
[1.02, 6.61], p = .047) remained significant independent predictors of ADHD persistence.
Stability of ADHD Subtypes
Of the 211 participants diagnosed with adult (i.e., persistent) ADHD, the most common 
childhood subtype was “combined” (55.4%), followed by the “inattentive” (24.6%) and 
“hyperactive-impulsive” (19.9%) subtypes.
Overall, childhood subtypes were stable into adulthood in 66.8% (n = 141) of the cases. The 
combined subtype was the most stable, with the majority of those with the combined 
subtype in childhood meeting criteria for the combined subtype in adulthood (78.6%; Figure 
1). The inattentive subtype was the least stable, with less than half (48.1%) retaining this 
symptom presentation in adulthood and the remainder transitioning to the combined 
subtype.
Of those 70 cases where a transition between childhood and adult subtypes occurred, the 
most common pathway of transition was from the inattentive subtype in childhood to the 
combined subtype in adulthood (38.6%), followed by combined to hyperactive-impulsive 
(21.4%), hyperactive-impulsive to combined (20.0%), combined to inattentive (14.3%), and 
hyperactive-impulsive to inattentive (5.7%). There were no transitions from the inattentive to 
hyperactive-impulsive subtypes.
Factors Associated With Childhood Subtype Stability
Those whose ADHD subtype in childhood remained stable into adulthood did not differ 
from those who transitioned to a different subtype in terms of age, gender, family history of 
ADHD, CD symptoms, or past treatment with stimulant medication (Table 4). Subtype 
stability was significantly less likely among those with the inattentive childhood subtype and 
more likely among those with the combined childhood subtype, with these differences 
remaining significant after Holm–Bonferroni correction.
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Multivariable analysis of subtype stability between childhood and adulthood revealed that, 
after adjustment for potential confounding, having the combined subtype in childhood was 
the only significant independent predictor of overall subtype stability (ORadj = 3.21, 95% CI 
= [1.25, 8.26], p = .018).
The stability of specific childhood subtypes was also explored. Stability of the hyperactive-
impulsive subtype was associated with greater odds of a family history of ADHD (ORadj = 
7.10, 95% CI = [1.85, 27.26]) and stability of the combined subtype was more likely among 
those with symptoms of CD (ORadj = 4.70, 95% CI = [1.82, 12.11], p = .003) and past 
stimulant treatment for ADHD (ORadj = 3.62, 95% CI = [1.87, 7.02], p = .001). There were 
no significant independent predictors of stability of the inattentive subtype and further 
analysis of transitions from each childhood subtype to a different subtype in adulthood did 
not yield any significant findings.
Discussion
To our knowledge, this study provides the first cross-national data on the persistence of 
ADHD into adulthood among a treatment seeking SUD population. ADHD in childhood and 
adolescence was highly prevalent (22.7%) and persistent: 72.8% of those meeting DSM-5 
criteria for childhood ADHD also met criteria for adult ADHD. ADHD persistence was 
predicted by a family history of ADHD and childhood CD symptoms, and independently 
associated with comorbid ASPD.
The high prevalence of ADHD in the current sample is consistent with previous research 
(van Emmerik-van Oortmerssen et al., 2012), as are the low rates of previously established 
formal ADHD diagnosis and treatment (Bernardi et al., 2012; Faraone, Spencer, Montano, & 
Biederman, 2004; Kaye, Darke, & Torok, 2013; McAweeney, Rogers, Huddleston, Moore, 
& Gentile, 2010). Moreover, we found a full syndrome ADHD persistence rate in adulthood 
that is two- to fivefold that observed in outcome studies of childhood ADHD among non-
SUD, clinically referred samples of ADHD patients. While two thirds of those with 
childhood ADHD may continue to have symptoms as adults to some extent, studies of 
ADHD persistence have typically found that only 15% to 35% of childhood cases of ADHD 
meet full diagnostic criteria for ADHD by adulthood (Biederman et al., 2011; Faraone et al., 
2006).
In contrast to the decline in persistence associated with increasing age found among 
longitudinal studies of children with ADHD (Biederman, Mick, & Faraone, 2000; 
Biederman et al., 2010; Faraone et al., 2006), the current study found no association between 
age and the persistence of symptoms, even for hyperactive-symptoms, which are typically 
more likely to remit with increasing age. This finding may reflect the developmental course 
of ADHD, such that the decline in symptom persistence may be steeper up until early 
adulthood than beyond. As suggested by prospective and retrospective studies of adult 
ADHD that have also found no effect of age on persistence (Karam et al., 2015; Kessler et 
al., 2005), once ADHD has persisted into adulthood, age-related remission may be less 
likely. Importantly, the higher persistence rates than among other populations observed here 
Kaye et al. Page 9
J Atten Disord. Author manuscript; available in PMC 2019 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
may also reflect a greater severity and chronicity of ADHD among those seeking treatment 
for SUDs.
Consistent with previous research among non-SUD populations (Biederman et al., 1996; 
Biederman et al., 2000; Biederman et al., 2011; Biederman et al., 2010; Hart, Lahey, Loeber, 
Applegate, & Frick, 1995), a family history of ADHD was the strongest predictor of the 
persistence of childhood ADHD into adulthood. The familiality and heritability of ADHD is 
well-documented. ADHD is a highly heritable disorder, with data from twin studies 
indicating that approximately 70% to 80% of the phenotypic variability is due to genetic 
influences (Faraone et al., 2005; Franke et al., 2012; Todd et al., 2001) and that heritability 
of clinically diagnosed ADHD remains high across the life span (Larsson, Chang, 
D’Onofrio, & Lichtenstein, 2014). Moreover, the developmental course of ADHD appears to 
have a strong genetic underpinning, with evidence for a primary role of genetic factors in 
ADHD symptom trajectories from childhood into adolescence (Pingault et al., 2015) and a 
higher familial risk for persistent ADHD than for ADHD that remits by adulthood (Franke et 
al., 2012).
As SUDs also have substantial heritability (≈0.5; Urbanoski & Kelly, 2012), it has been 
hypothesized that ADHD-SUD comorbidity reflects a shared genetic liability to both 
disorders (Biederman et al., 2008; Carpentier et al., 2013; Derks, Vink, Willemsen, van den 
Brink, & Boomsma, 2014) and to externalizing pathology more broadly, including ASPD 
(Carragher et al., 2014). The association between familial ADHD and persistence of 
childhood ADHD in the current study suggests that this form of comorbidity in adulthood 
reflects a more severe phenotype of ADHD with a greater genetic loading. As all of the 
participants in the current study were seeking SUD treatment, the relative contribution of a 
genetic liability to persistent ADHD to the development and maintenance of SUD is unclear.
The presence of childhood CD symptoms also significantly predicted ADHD persistence. 
Moreover, ADHD continued to be associated with ASPD in adulthood, even after 
controlling for antisocial behavior associated with illicit drug use. These findings support 
those of earlier work in clinical SUD samples showing higher rates of ASPD among those 
with comorbid adult ADHD (Carpentier, van Gogh, Knapen, Buitelaar, & De Jong, 2011).
ADHD is generally associated with an earlier onset and more severe course of SUDs. The 
present study, however, did not find any significant differences in SUD trajectories according 
to ADHD persistence or symptom presentation. This may reflect the nature of the current 
sample in that SUDs among a treatment seeking sample are likely to be at the more severe 
end of the spectrum (J. T. Young et al., 2015), regardless of whether ADHD has persisted or 
remitted. It is also possible that differences in SUD trajectories were obscured by the use of 
a categorical, rather than dimensional, approach to the measurement of ADHD. Previous 
research has found that when ADHD is measured on a continuum, increased symptom 
levels, even if below the diagnostic threshold, are associated with increased odds of SUD 
and that such approaches may be more sensitive in identifying clinically important variations 
in SUD risk (Ameringer & Leventhal, 2013; Elkins et al., 2007).
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Although earlier onset and greater extent of illicit stimulant (i.e., cocaine, amphetamine) use 
among the persistent ADHD group was not significant after multiple comparison correction, 
the direction of the findings are consistent with some studies showing that, among treatment 
and community SUD samples, adult ADHD symptoms are associated with a preference for 
stimulants over other drug classes (Bihlar Muld, Jokinen, Bolte, & Hirvikoski, 2013; 
Ginsberg, Hirvikoski, & Lindefors, 2010), higher rates of stimulant dependence, and a 
greater frequency and chronicity of stimulant use (Kaye et al., 2013; Wilens et al., 2007; J. 
T. Young et al., 2015). As stimulants are considered effective first-line pharmacotherapy for 
ADHD, illicit stimulant use among those with ADHD is often speculated to be a form of 
“self-medication” of undiagnosed or untreated ADHD (Wilens et al., 2007; S. Young & 
Sedgwick, 2015). Other studies, however, have not found a preference for stimulants among 
those with ADHD (van Emmerik-van Oortmerssen et al., 2012), possibly reflecting the high 
levels of polydrug use that are typical among illicit drug users (Darke & Hall, 1995; van 
Emmerik-van Oortmerssen et al., 2012). Although a preference for stimulants associated 
with adult ADHD has not been unequivocally demonstrated, the persistence of ADHD may 
make longer term, higher frequency, and, consequently, problematic use of stimulants for 
their reinforcing and possibly “medicating” effects more likely.
Childhood maltreatment (e.g., physical/sexual abuse, neglect) has been associated with 
childhood and adult ADHD (Briscoe-Smith & Hinshaw, 2006; Fuller-Thomson & Lewis, 
2015; Ouyang, Fang, Mercy, Perou, & Grosse, 2008), while psychosocial childhood 
adversity more broadly has been shown to predict ADHD in childhood (Biederman et al., 
1995; Kessler et al., 2005) and the persistence of ADHD into late adolescence (Biederman et 
al., 1996). In the current study, however, childhood adversity was not independently 
associated with ADHD persistence. Previous studies that have specifically examined the role 
of childhood adversity in predicting the persistence of ADHD into adulthood have likewise 
failed to demonstrate such an association (Kessler et al., 2005; Lara et al., 2009; McLaughlin 
et al., 2010). Childhood adversity is a well-documented antecedent to problematic substance 
use (Darke, 2013). Its potential moderating effect on ADHD persistence among those with 
SUDs, however, is not borne out by the current study, perhaps due to the high prevalence of 
childhood trauma in both the persistent and remitted ADHD groups, and has yet to be 
determined. Further studies may help to elucidate this relationship.
In accordance with previous research demonstrating an association between the combined 
subtype of ADHD and SUDs (Nogueira et al., 2014; Obermeit et al., 2013; Sprafkin et al., 
2007; Tamm et al., 2012; Wilens et al., 2009), the combined subtype was the most common 
symptom presentation in both childhood and adult ADHD in this sample. Moreover, the 
combined subtype was the most stable presentation between childhood and adulthood, and 
this stability was significantly associated with a history of CD symptoms and past stimulant 
medication treatment of ADHD. ADHD symptoms causing sufficient impairment to require 
stimulant medication treatment and comorbid symptoms of CD indicate a greater severity of 
childhood ADHD. As such, a more severe adult symptom presentation with persistence of 
both inattentive and hyperactive-impulsive symptoms is not surprising and highlights the 
need to improve identification and management of adult ADHD among those with SUDs.
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These findings, along with the similarity in prevalence of the hyperactive-impulsive and 
inattentive subtypes throughout childhood and adulthood, suggest that SUDs may be 
associated with a different clinical manifestation and trajectory of ADHD than that typically 
seen in non-SUD populations. Among clinical and community samples, the inattentive 
subtype predominates (Wilens et al., 2009; Willcutt, 2012) and hyperactive-impulsive 
symptoms in childhood are more likely to remit by adulthood or become less impairing as 
people learn to channel their hyperactivity-impulsivity into careers and hobbies that will 
accommodate these tendencies. It would thus be reasonable to expect a transition from the 
combined subtype in childhood to the inattentive subtype in adulthood in a greater 
proportion of cases than we observed. Only one in seven transitioned from the combined to 
the inattentive subtype, whereas almost half of those with the inattentive and hyperactive-
impulsive subtypes in childhood transitioned to a combined subtype in adulthood. Although 
we were unable to identify any factors significantly associated with transitioning to the 
combined subtype, the developmental trajectories of ADHD symptoms in this group, and 
greater persistence of hyperactive-impulsive symptoms in particular, warrant further 
investigation to illuminate the likely mechanisms involved. It is possible that persistent 
impulsivity increases the likelihood of developing SUDs, but it is also plausible that chronic 
drug use, in and of itself, impairs prefrontal inhibitory function, via reduced dopamine 
transmission, resulting in greater impulsivity and hyperactivity (Volkow, Fowler, Wang, 
Baler, & Telang, 2009).
There are a number of methodological limitations to be acknowledged. First, the 
representativeness of the sample of SUD treatment seekers in this study should be 
considered. Although the potential for selection bias cannot be discounted, there were no 
significant differences in the demographic and SUD profiles between those who participated 
in the study and those who dropped out prior to the full assessment phase (van de Glind et 
al., 2013). Therefore, potential bias due to study attrition is likely to be non-differential. 
Second, this was a predominantly male, Caucasian sample. As such, the findings may not be 
generalizable to populations with greater gender and ethnic diversity. It should be noted, 
however, that the gender distribution in our sample is consistent with that found in other 
SUD treatment seeking samples (European Monitoring Centre for Drugs and Drug 
Addiction, 2011). Third, the findings were based on retrospective self-report. With regard to 
the assessment of substance use history, carefully collected self-report data have been found 
to be a sufficiently reliable and valid measure for drug use patterns and associated problems 
(Darke, 1998; Ledgerwood, Goldberger, Risk, Lewis, & Price, 2008). In cases where family 
networks were fractured, obtaining collateral information to support recall of childhood 
events was difficult. As such, information pertaining to familial and environmental risk 
factors may be subject to recall bias. Due to the likelihood that many participants would not 
have had access to informants willing or able to provide information confirming the 
presence of ADHD symptoms in childhood, collateral report was not a requirement for the 
diagnostic assessment of ADHD, nor was the lack of collateral information a criterion for 
exclusion from the study. Although the use of retrospective self-report may potentially lead 
to an underreporting of the presence and severity of symptoms of ADHD (Barkley, Fischer, 
Smallish, & Fletcher, 2002), most adults have been found to accurately report their own 
symptoms of childhood and adult ADHD (Murphy & Schachar, 2000). Moreover, studies 
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have shown that, among those with a clinical diagnosis of adult ADHD, retrospective 
informant reports of childhood symptoms do not improve diagnostic accuracy over self-
report and may be even less reliable than the patient’s own recall (Breda et al., 2015; Sandra 
Kooij et al., 2008). Finally, due to the cross-sectional study design, inferences regarding 
causal associations cannot be made. Although the predictors of persistence identified in the 
current study are consistent with the known risk factors for childhood ADHD (Banerjee, 
Middleton, & Faraone, 2007; Froehlich et al., 2011; Warikoo & Faraone, 2013) per se, it is 
possible that they are also associated with a greater severity of childhood ADHD which, in 
turn, is more likely to persist.
Although ADHD is prevalent and persistent among SUD treatment seekers and is associated 
with a more severe phenotype that is less likely to remit, it typically remains undiagnosed 
and untreated. Routine screening and follow-up assessment for ADHD and other 
externalizing disorders at treatment intake, to identify and manage this complex comorbidity, 
is critical to improving treatment outcomes. Moreover, given the neurobiological and clinical 
differences between persistent and remitted ADHD, there is a need for follow-up studies of 
those diagnosed in adulthood. In particular, studies investigating the clinical outcomes of 
treatment for comorbid adult ADHD and SUD and randomized controlled trials evaluating 
the sequence and effect of different treatment strategies are warranted.
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Figure 1. 
Stability of childhood ADHD subtypes among those with persistent ADHD.
aIndicates subtype stability (i.e., child subtype = adult subtype).
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Table 1
Sample Characteristics According to Persistence or Remission of Childhood ADHD Into Adulthood.
Persistent ADHD
(n = 211)
Remitted ADHD
(n = 79)
Unadjusted OR (95% CI) or t-
statistic
Uncorrected
p values
Mean age (SD) 35.6 (9.6) 36.1 (10.4) t287 = −0.38 p = .704
Range 18–63 18–60
% Male 76.8 79.7 OR 1.19 [0.63, 2.25] p = .590
% Caucasian 95.8 93.0 OR 1.74 [0.55, 5.52] p = .345
% Graduated high schoola 47.6 40.3 OR 1.35 [0.76, 2.39] p = .310
% Unemployedb 72.8 74.4 OR 0.92 [0.51, 1.67] p = .788
% Married/de facto relationshipc 10.3 17.2 OR 0.55 [0.25, 1.24] p = .151
% Inpatient SUD treatment settingd 31.6 41.8 OR 0.64 [0.38, 1.10] p = .105
% Diagnosed with ADHD prior to study 
entryd
21.1 24.1 OR 0.84 [0.46, 1.56] p = .583
% Past stimulant medication treatment 
for ADHDe
16.1 10.3 OR 1.68 [0.74, 3.81] p = .216
% Current stimulant medication 
treatment for ADHDf
  8.6   5.7 OR 1.56 [0.32, 7.46] p = .580
Note. OR = odds ratios; CI = confidence intervals; SUD = substance use disorder.
a
n = 235.
b
n = 280.
c
n = 248.
d
n = 288.
e
n = 283.
f
n = 151.
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Table 2
Drug Use Correlates of ADHD Persistence.
Persistent ADHD
(n = 211)
Remitted ADHD
(n = 79) Unadjusted OR (95% CI) or t-statistic
Uncorrected
p values
Primary substance of concern (%)a
 Alcohol 35.1 51.9 OR 0.50 [0.29, 0.85]
  p = .010†
 Illicit drugs 64.9 48.1 OR 2.00 [1.18, 3.40]
  p = .010†
  Heroin 12.0   9.1 OR 1.37 [0.57, 3.30] p = .488
  Amphetamine 17.8   6.5 OR 3.12 [1.18, 8.25]
  p = .022†
  Cocaine 12.0   2.6 OR 5.12 [1.18, 22.17]
  p = .029†
  Cannabis 15.4 22.1 OR 0.64 [0.33, 1.24] p = .186
  Benzodiazepines   3.8   5.2 OR 0.73 [0.21, 2.50] p = .616
Age of first use (mean)
 Nicotine 14.3 14.4 t143 = −0.17 p = .867
 Alcohol (<5 glasses) 14.7 15.2 t182 = −0.56 p = .579
 Alcohol (>5 glasses) 16.7 18.7 t83 = −1.72 p = .089
 Heroin 22.3 20.1 t69 = 1.45 p = .150
 Methadone 28.4 32.4 t39 = −0.91 p = .368
 Cocaine 21.5 21.0 t132 = 0.45 p = .653
 Amphetamines 18.9 21.2 t135 = −2.11
    p = .037††
 Cannabis 15.9 16.4 t189 = −0.75 p = .454
 Benzodiazepines 22.8 24.3 t114 = −0.84 p = .403
Regular use (mean years)
 Nicotine 20.3 19.1 t137 = 0.63 p = .531
 Alcohol (>5 glasses) 13.4 14.0 t196 = −0.37 p = .711
 Heroin   7.7   7.4 t61 = 0.12 p = .906
 Methadone   3.8   3.7 t37 = 0.08 p = .936
 Cocaine   5.8   3.3 t69 = 2.56
    p = .013††
 Amphetamines   8.7   6.3 t123 = 1.21 p = .227
 Cannabis 12.0 12.2 t172 = −0.10 p = .917
 Benzodiazepines   7.2   5.5 t104 = 1.13 p = .260
Days used past month (mean)
 Nicotine 28.1 26.3 t53 = 1.04 p = .302
 Alcohol (>5 glasses) 10.3 13.5 t202 = −1.63 p = .105
 Heroin   3.2   1.1 t62 = 0.94 p = .351
 Methadone 11.7 16.0 t39 = −0.68 p = .502
 Cocaine   3.6   1.1 t70 = 2.10
    p = .040††
 Amphetamines   3.9   3.3 t118 = 0.28 p = .784
 Cannabis   9.5 11.9 t172 = −1.09 p = .277
J Atten Disord. Author manuscript; available in PMC 2019 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Kaye et al. Page 26
Persistent ADHD
(n = 211)
Remitted ADHD
(n = 79) Unadjusted OR (95% CI) or t-statistic
Uncorrected
p values
 Benzodiazepines 11.8 14.8 t106 = −1.04 p = .301
Polydrug use (mean no. drug classes)
 Lifetime   4.0   3.4 t259 = 2.05
      p = .041†††
 Recent   1.8   1.6 t259 = 0.96 p = .336
Note. OR = odds ratios; CI = confidence intervals.
a
n = 285.
†p value not significant after correcting for multiple comparisons (corrected p < .007).
††p value not significant after correcting for multiple comparisons (corrected p < .006).
†††p value not significant after correcting for multiple comparisons (corrected p < .025).
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Table 3
Early Predictors of ADHD Persistence.
Persistent ADHD (n = 
211)
Remitted ADHD (n = 
79) Unadjusted OR (95% CI) Uncorrected p values
% ADHD childhood subtype
 Inattentive 24.6 25.3 OR 0.96 [0.53, 1.75] p = .906
 Hyperactive-impulsive 19.9 32.9 OR 0.51 [0.28, 0.90]
  p = .021†
 Combined 55.5 41.8 OR 1.74 [1.03, 2.93]
  p = .039†
% Family history of ADHDa 38.7 21.5 OR 2.30 [1.17, 4.55]   p = .016*
% In utero exposureb
 Nicotine 37.8 40.8 OR 0.88 [0.50, 1.55] p = .657
 Alcohol 15.6 18.6 OR 0.81 [0.39, 1.68] p = .573
 Illicit drugs   1.2   2.9 OR 0.40 [0.05, 2.88] p = .361
% Childhood adversityc
 Trauma
  Sexual abuse 23.4 18.3 OR 1.37 [0.68, 2.74] p = .381
  Physical abuse 40.6 47.9 OR 0.74 [0.43, 1.29] p = .294
  Emotional abuse 55.4 49.3 OR 1.28 [0.74, 2.22] p = .383
  Other trauma 76.3 60.0 OR 2.15 [1.19, 3.88]
    p = .012††
  Any trauma 84.0 81.7 OR 1.18 [0.57, 2.43] p = .660
 Family violence 40.6 40.8 OR 0.99 [0.56, 1.73] p = .968
 Neglect 41.4 25.4 OR 2.08 [1.12, 3.84]
    p = .020††
% Conduct disorder symptomsd 69.0 51.4 OR 2.10 [1.21, 3.67]   p = .009*
Note. OR = odds ratios; CI = confidence intervals.
a
n = 172.
b
n = 243.
c
n = 246.
d
n = 259.
†p value not significant after correcting for multiple comparisons (corrected p < .017).
††p value not significant after correcting for multiple comparisons (corrected p < .008).
*p value significant at p < .05.
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Table 4
Factors Associated With Childhood Subtype Stability.
Stable childhood 
subtype (n = 141)
Unstable childhood 
subtype (n = 70) Unadjusted OR (95% CI)
Uncorrected
p values
Mean age 35.5 35.8 t208 = −0.18 p = .860
% Male 78.0 74.3 OR 0.81 [0.42, 1.59] p = .546
% Family history of ADHD 37.3 42.3 OR 0.81 [0.32, 2.04] p = .657
% Conduct disorder symptoms 73.3 61.2 OR 1.74 [0.92, 3.30] p = .087
% Past stimulant medication treatment for 
ADHD
16.8 14.7 OR 1.17 [0.52, 2.62] p = .703
% Childhood subtype
  Inattentive 17.7 38.6 OR 0.34 [0.18, 0.66]
  p = .001*
  Hyperactive-impulsive 17.0 25.7 OR 0.59 [0.30, 1.18] p = .139
  Combined 65.2 35.7 OR 3.38 [1.86, 6.15]
  p < .001*
Note. OR = odds ratios; CI = confidence intervals.
*p value significant after correcting for multiple comparisons (corrected p < .017).
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